BioNTech and Pfizer have dosed participants in the first cohort of a Phase I/II clinical trial of Covid-19 vaccine candidate BNT162 in Germany.
Dosing in the trial was commenced on 23 April and 12 participants have received the vaccine so far.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The companies also intend to trial BNT162 in the US following regulatory approval.
